Segall Bryant & Hamill, LLC Cytokinetics Inc Transaction History
Segall Bryant & Hamill, LLC
- $6.35 Billion
- Q1 2025
A detailed history of Segall Bryant & Hamill, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 69,543 shares of CYTK stock, worth $2.35 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
69,543
Previous 71,500
2.74%
Holding current value
$2.35 Million
Previous $3.36 Million
16.92%
% of portfolio
0.04%
Previous 0.05%
Shares
4 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
127MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$496 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$400 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$336 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$270 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$206 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.18B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...